



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/431193/2011

European Medicines Agency decision P/141/2011

6 June 2011

on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMA-000366-PIP01-08-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/141/2011

6 June 2011

on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMA-000366-PIP01-08-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/102/2009 issued on 18 May 2009, the decision P/102/2010 issued on 8 June 2010 and the decision P/1/2011 issued on 3 January 2011,

Having regard to the application submitted by Abbott Laboratories Ltd on 7 March 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 May 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for adalimumab (Humira), solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Abbott Laboratories Ltd, Abbott House, Vanwall Business Park, Vanwall Road, SL6 4XE Maidenhead, Berkshire, United Kingdom.

Done at London, 6 June 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/326762/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000366-PIP01-08-M04

Scope of the application

Active substance(s):

Adalimumab

Invented name:

Humira

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

Treatment of Crohn's disease

Treatment of psoriasis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Abbott Laboratories Ltd

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Abbott Laboratories Ltd, submitted to the European Medicines Agency on 7 March 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/102/2009 issued on 18 May 2009, the decision P/102/2010 issued on 8 June 2010 and the decision P/1/2011 issued on 3 January 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 23 March 2011.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan were modified. One study was removed from the Paediatric Investigation Plan.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion,

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 20 May 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

The waiver applies to:

- paediatric population from birth to less than 2 years of age for solution for injection for subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

1.2. Condition: Treatment of Crohn's disease

The waiver applies to:

- paediatric population from birth to less than 6 years of age for solution for injection for subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.3. Condition: Treatment of psoriasis

The waiver applies to:

- paediatric population from birth to less than 4 years of age for solution for injection for subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of polyarticular juvenile idiopathic arthritis, treatment of enthesitis related arthritis.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	3	Study 1 A multicenter, randomised, double-blind, placebo-controlled study of the safety, efficacy, and pharmacokinetics of the human anti-TNF monoclonal antibody adalimumab in children with polyarticular juvenile idiopathic arthritis Study 2 Compassionate use study of adalimumab in children from 2 to less than 4 Years old or age 4 and above weighing less than 15 kg with active juvenile idiopathic arthritis (JIA). Study3 A double-blind, placebo-controlled, multicenter study of the efficacy and safety of the human anti-TNF monoclonal antibody adalimumab in paediatric patients with enthesitis-related arthritis.

2.2. Condition: Treatment of Crohn's disease

2.2.1. Indication(s) targeted by the PIP

Treatment of Crohn's disease.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Solution for injection.

2.2.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.

Area	Number of studies	Description
Non-clinical	0	Not applicable.
Clinical	1	Study 4 A multi-centre, double-blind (DB) study to evaluate the safety, efficacy and pharmacokinetics (PK) of the human anti-TNF monoclonal antibody adalimumab in paediatric patients with moderate to severe Crohn's disease (CD).

2.3. Condition: Treatment of psoriasis

2.3.1. Indication(s) targeted by the PIP

Treatment of severe chronic plaque psoriasis

2.3.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 to less than 18 years of age.

2.3.3. Pharmaceutical form(s)

Solution for injection

2.3.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	1	Study 5 A multi-centre, randomised, double-dummy, double-blind study evaluating two doses of adalimumab versus methotrexate (MTX) in paediatric patients with chronic plaque psoriasis (Ps).

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety or efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2013
Deferral for some or all studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Rheumatoid arthritis

Authorised indications:

the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.

the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

2. Treatment of Polyarticular juvenile idiopathic arthritis

Authorised indications:

Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in adolescents aged 13 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

3. Treatment of Psoriatic arthritis

Authorised indications:

Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.

4. Treatment of Ankylosing spondylitis

Authorised indications:

Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

5. Treatment of Crohn's disease

Authorised indications:

Humira is indicated for treatment of severe, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

6. Treatment of Psoriasis

Authorised indications:

Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content (concentration)	Package size
EU/1/03/256/001	Humira	40 mg/0.8 ml	Solution for injection	Subcutaneous use	vial (glass)	0.8 ml (40 mg/0.8ml)	2 carton pack. Each carton contains: 1 vial + 1 syringe + 1 sterile adapter + 2 alcohol pads
EU/1/03/256/002	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled syringe (glass)	0.8 ml (40 mg/0.8ml)	1 pre-filled syringe + 1 alcohol pad
EU/1/03/256/003	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled syringe (glass)	0.8 ml (40 mg/0.8ml)	2 pre-filled syringes + 2 alcohol pads
EU/1/03/256/004	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled syringe (glass)	0.8 ml (40 mg/0.8ml)	4 pre-filled syringes + 4 alcohol pads
EU/1/03/256/005	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled syringe (glass)	0.8 ml (40 mg/0.8ml)	6 pre-filled syringes + 6 alcohol pads
EU/1/03/256/006	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled syringe (glass)	0.8 ml (40 mg/0.8ml)	1 pre-filled syringe with needleguard + 1 alcohol pad
EU/1/03/256/007	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled pen (glass)	0.8 ml (40 mg/0.8ml)	1 pre-filled pen + 1 alcohol pad in a blister

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content (concentration)	Package size
EU/1/03/256/008	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled pen (glass)	0.8 ml (40 mg/0.8ml)	2 pre-filled pens + 2 alcohol pads in a blister
EU/1/03/256/009	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled pen (glass)	0.8 ml (40 mg/0.8ml)	4 pre-filled pens + 4 alcohol pads in a blister
EU/1/03/256/010	Humira	40 mg	Solution for injection	Subcutaneous use	pre-filled pen (glass)	0.8 ml (40 mg/0.8ml)	6 pre-filled pens + 6 alcohol pads in a blister